1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Dosage Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of diabetes
4.1.2. Restraints
4.1.2.1. Side effects associated with diabetic drugs
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.1.3. Biguanides*
9.1.4. Introduction
9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.1.5.1. Metformin
9.1.6. Alpha-glucosidase inhibitors
9.1.7. Dopamine -D2 Receptor Agonist
9.1.7.1. Bromocriptin (Cycloset)
9.1.7.2. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
9.1.7.3. Invokana (Canagliflozin)
9.1.7.4. Jardiance (Empagliflozin)
9.1.7.5. Farxiga/Forxiga (Dapagliflozin)
9.1.7.6. Suglat (Ipragliflozin)
9.1.8. Dipeptidyl Peptidase – 4 (DPP-4) Inhibitors
9.1.8.1. Januvia (Sitagliptin)
9.1.8.2. Onglyza (Saxagliptin)
9.1.8.3. Tradjenta (Linagliptin)
9.1.8.4. Vipidia/Nesina (Alogliptin)
9.1.8.5. Galvus (Vildagliptin)
9.1.9. Sulfonylureas
9.1.10. Meglitinides
10. By Dosage Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
10.1.2. Market Attractiveness Index, By Dosage Type
10.2. Liquid*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Capsule
10.4. Tablet
11. By Distribution Channel
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Glenmark Pharma*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Abbott
14.3. Biocon
14.4. Sanofi
14.5. Sunpharma
14.6. Novartis
14.7. Novo Nordisk
14.8. Merck
14.9. GlaxoSmithKline
14.10. Bristol-Myers Squibb
15. Appendix
15.1. About Us and Services
15.2. Contact Us